Anixa Biosciences, Inc.

Rentabilité sur six mois: +5.7%
Rendement en dividendes: 0%
Secteur: Healthcare

3.34 $

0 $ 0%
2.13 $
3.97 $

paper.min_max_per_year

Calendrier des promotions Anixa Biosciences, Inc.

À propos de l'entreprise Anixa Biosciences, Inc.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Paramètres de base

IPO date
1987-01-01
ISIN
US03528H1095
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт

Grade

Sous-estimation
Nom Signification Grade
P/S 470.6 1
P/BV 6.7 1
P/E 0 0
Efficacité
Nom Signification Grade
ROA -53.29 0
ROE -56.63 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.0183 10
Debt/Ratio 0.0107 10
Debt/Equity 0.1431 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % -80.91 0
Rentabilité Ebitda, % 30.53 5
Rentabilité EPS, % -14.9 0

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 3.34 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 3.42 $ 0 $ 0 $ -2.2 % 0 % 0 %
common.calendar.number_days.30d 2.5 $ 2.76 $ 3.6 $ 33.6 % 0 % 0 %
common.calendar.number_days.90d 2.58 $ 2.38 $ 3.6 $ 29.46 % 0 % 0 %
common.calendar.number_days.180d 3.16 $ 2.13 $ 3.6 $ 5.7 % 0 % 0 %
common.calendar.number_days.1y 3.29 $ 2.13 $ 3.97 $ 1.52 % 0 % 0 %
common.calendar.number_days.3y 4.07 $ 2.13 $ 6.15 $ -17.94 % 0 % 0 %
common.calendar.number_days.5y 2.88 $ 1.79 $ 7.14 $ 15.97 % 0 % 0 %
common.calendar.number_days.10y 0.6001 $ 0.6001 $ 7.14 $ 556.57 % 0 % 0 %
common.calendar.number_days.ytd 2.8 $ 2.13 $ 3.6 $ 19.29 % 0 % 0 %

Principaux propriétaires

Entreprises similaires



Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Amit Kumar Ph.D. CEO, Chairman & Co-Chair of CBAB 1.29M 1964 (61 année)
Mr. Michael J. Catelani CPA, MBA President, COO, CFO & Corporate Secretary 788.83k 1967 (58 années)
Mr. John Roop Senior Vice President of Engineering 275k 1950 (75 années)
Dr. Pamela D. Garzone Ph.D. Chief Development Officer & Chair Breast Cancer Clinical Advisory Board 1955 (70 années)

Informations sur l'entreprise

Adresse: United States, San Jose. CA, 3150 Almaden Expressway - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.anixa.com